All Oncology News

Trastuzumab Plus Pertuzumab Provides Sustained iDFS Benefit in HER2+ Breast Cancer

May 1st 2024

Ashling Wahner

A chemotherapy-free regimen of trastuzumab plus pertuzumab generated a strong 3-year iDFS rate in patients with HER2-positive early breast cancer.

Final USPSTF Recommendation Statement Advises Women Begin Receiving Mammograms at 40 Years Old

May 1st 2024

Megan Hollasch

The United States Preventive Services Task Force final breast cancer screening recommendation statement advises that women aged 40 begin biennial screening.

Utah Governor’s Medal Given to Neli Ulrich, PhD, MS, for Outstanding Research and Leadership

May 1st 2024

Huntsman Cancer Institute

Neli Ulrich, PhD, MS, of Huntsman Cancer Institute, has been awarded the 2024 Governor’s Medal for Science and Technology.

SLS009 Plus Venetoclax/Azacitidine Produces Responses in R/R AML, Including ASXL1+ Disease

May 1st 2024

Chris Ryan

SLS009 plus venetoclax and azacitidine elicited responses in patients with relapsed/refractory AML, particularly in those harboring ASXL1 mutations.

EVT801 Is Well Tolerated, Elicits Disease Control in Advanced Ovarian Cancer

May 1st 2024

Chris Ryan

Treatment with EVT801 was well tolerated and led to a stable disease rate of 46% in patients with advanced ovarian cancer.

Frontline Pembrolizumab Plus Trastuzumab/Chemo Meets OS End Point in HER2+ Gastric/GEJ Cancer

May 1st 2024

Ryan Scott

Frontline pembrolizumab plus trastuzumab/chemotherapy improved overall survival in HER2-positive, unresectable or metastatic gastric/GEJ cancer.

Immunogenomics Demonstrate Predictive Capability to Immunotherapy Resistance in Uveal Melanoma

May 1st 2024

Kyle Doherty

Immunogenomic information displays predictive capability in terms of immunotherapy resistance in metastatic uveal melanoma.

Giants of Cancer Care® Announces the 12th Annual Class of Inductees

May 1st 2024

The 15 inductees have been selected by their peers for their remarkable achievements in oncology research and clinical practice.

Glecirasib Generates Durable Responses in Pretreated Advanced KRAS G12C+ NSCLC

April 30th 2024

Chris Ryan

Glecirasib elicited responses and demonstrated a manageable safety profile in patients with pretreated advanced NSCLC harboring KRAS G12C mutations.

Patient Factors, Toxicities Key to Selecting NALIRIFOX or Other Chemo Options in Advanced Pancreatic Cancer

April 30th 2024

Jax DiEugenio

Kian-Huat Lim, MD, PhD, discusses the current treatment landscape for metastatic pancreatic cancer.

Expansion of Luspatercept Indication Underscores Evolving Treatment Landscape for Low-Risk MDS

April 30th 2024

Ryan Scott

Benjamin Tomlinson, MD, discusses the first-line approval of luspatercept and other ongoing research in low-risk MDS.

Examining Potential Markers of Osteosarcoma Stem Cells Is at the Forefront of Research

April 30th 2024

Megan Hollasch

R. Lor Randall, MD, FACS, discusses research examining ALDH1A1 and CD44, potential markers of osteosarcoma stem cells, and how further research may be warranted with cancer stem cells.

Studying Endometrial Cancer in Black Women

April 30th 2024

Sylvester Comprehensive Cancer Center

Two new grants from the U.S. Department of Defense will support Sylvester Comprehensive Cancer Center studies of endometrial cancer in Black women.

NK Cell Therapy IGNK001 Receives FDA Orphan Drug Designation for AML

April 30th 2024

Ashling Wahner

The investigational therapy IGNK001 has received orphan drug designation from the FDA for patients with acute myeloid leukemia.

Chidamide Plus R-CHOP Approved in China for MYC/BCL2–Expressing DLBCL

April 30th 2024

Courtney Flaherty

Chidamide plus R-CHOP has received approval from China’s NMPA for the management of diffuse large B-cell lymphoma.